Corvus Pharmaceuticals, Inc. CRVS
11.37 USD +0.02 (+0.18%)
At closeNov 11, 2026, 4:02 AM EST
11.31 -0.06 -0.53%
Pre-market · Nov 11, 4:02 AM ET
11.09 Day range 11.78
6.39 52-week range 26.95
- YTD
- +47.66%
- 1 year
- +43.74%
News
seekingalpha.com Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product Corvus Pharmaceuticals offers a catalyst-rich, fully funded pipeline, highlighted by soquelitinib's potential for durable remission in atopic dermatitis and PTCL. Soquelitinib's post-treatment…
seekingalpha.com Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027 Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by soquelitinib's advancing clinical programs in r/r PTCL and autoimmune indications. The phase 3 trial for relapsed/refractory PTCL…
globenewswire.com Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership…
seekingalpha.com Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
marketbeat.com What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call Corvus Pharmaceuticals NASDAQ: CRVS reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug,…
benzinga.com Corvus Pharma Q3 2026 Earnings Call Transcript Corvus Pharma (NASDAQ:CRVS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Corvus Pharma Q3 EPS $(0.22), Inline Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.22) per share which met the analyst consensus estimate. This is a 83.33 percent decrease over losses of $(0.12) per share from the same…
globenewswire.com Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious…
benzinga.com Corvus Pharma Q2 2026 Earnings Call Transcript Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought…